A vaccine for periodontal gum disease, which affects a third of all adults globally, is in development following a $14 million investment into newly-formed biotech company Denteric Pty Ltd.
The company was set up to develop and commercialise the research outputs of a long-running program originating from the University of Melbourne working in collaboration with CSL, Australia’s largest biotechnology company.
The announcement was made at the University’s recently officially launched Centre for Oral Health Research (COHR).
Denteric will focus on developing a therapeutic vaccine for treating periodontal disease.
“My team has been developing this critical treatment for periodontal disease over many years at the University of Melbourne,” said University of Melbourne Professor Eric Reynolds AO, founder and CEO of the Oral Health CRC, now COHR.
“[Now], in a true partnership with the Australian Government and private capital, we have launched a company which will bring a Melbourne-developed gum disease therapy to market.”